-
Tytuł:
-
Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study.
-
Autorzy:
-
Kissling E; Epiconcept, Paris, France.
Pozo F; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Martínez-Baz I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
Buda S; Robert Koch Institut, Berlin, Germany.
Vilcu AM; INSERM, Sorbonne Université, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Domegan L; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Mazagatos C; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Dijkstra F; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Latorre-Margalef N; The Public Health Agency of Sweden, Stockholm, Sweden.
Kurečić Filipović S; Croatian Institute of Public Health, Zagreb, Croatia.
Machado A; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Lazar M; 'Cantacuzino' National Military Medical Institute for Research and Development, Bucharest, Romania.
Casado I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
Dürrwald R; Robert Koch Institut, Berlin, Germany.
van der Werf S; Unité de Génétique Moléculaire des Virus à ARN, Institut Pasteur, Université Paris Cité, UMR 3569 CNRS, Paris, France.; CNR virus des infections respiratoires, Institut Pasteur, Paris, France.
O'Donnell J; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Linares Dopido JA; Subdirección de Epidemiología, Dirección General de Salud Pública, Servicio Extremeño de Salud, Extremadura, Spain.
Meijer A; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Riess M; The Public Health Agency of Sweden, Stockholm, Sweden.
Višekruna Vučina V; Croatian Institute of Public Health, Zagreb, Croatia.
Rodrigues AP; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Mihai ME; 'Cantacuzino' National Military Medical Institute for Research and Development, Bucharest, Romania.
Castilla J; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
Goerlitz L; Robert Koch Institut, Berlin, Germany.
Falchi A; Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.
Connell J; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Castrillejo D; Servicio de Epidemiología, DGSP, Consejería de Políticas Sociales, Salud Pública y Bienestar Animal, Ciudad Autónoma de Melilla, Melilla, Spain.
Hooiveld M; Nivel, Utrecht, The Netherlands.
Carnahan A; The Public Health Agency of Sweden, Stockholm, Sweden.
Ilić M; Croatian Institute of Public Health, Zagreb, Croatia.
Guiomar R; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Ivanciuc A; 'Cantacuzino' National Military Medical Institute for Research and Development, Bucharest, Romania.
Maurel M; Epiconcept, Paris, France.
Omokanye A; European Centre for Disease Prevention and Control, Stockholm, Sweden.
Valenciano M; Epiconcept, Paris, France.
-
Corporate Authors:
-
I-MOVE study team
-
Źródło:
-
Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2023 Jan; Vol. 17 (1), pp. e13069. Date of Electronic Publication: 2022 Nov 21.
-
Typ publikacji:
-
Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Oxford, UK : Wiley, c2007-
-
MeSH Terms:
-
Influenza A Virus, H1N1 Subtype*
Influenza Vaccines*
Influenza, Human*/epidemiology
Influenza, Human*/prevention & control
Humans ; Case-Control Studies ; Europe/epidemiology ; Influenza A Virus, H3N2 Subtype/genetics ; Primary Health Care ; Vaccination ; Vaccine Efficacy ; Male ; Female ; Infant, Newborn ; Infant ; Child, Preschool ; Child ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged
-
References:
-
Euro Surveill. 2022 Apr;27(15):. (PMID: 35426361)
Euro Surveill. 2013 Jan 31;18(5):. (PMID: 23399424)
Euro Surveill. 2012 Sep 27;17(39):. (PMID: 23041022)
Euro Surveill. 2020 Mar;25(10):. (PMID: 32183932)
Vaccine. 2020 Feb 18;38(8):1925-1932. (PMID: 31982263)
Euro Surveill. 2014 Feb 13;19(6):. (PMID: 24556348)
PLoS One. 2011;6(11):e27622. (PMID: 22110695)
Curr Opin Virol. 2014 Oct;8:85-9. (PMID: 25108824)
Euro Surveill. 2009 Nov 05;14(44):. (PMID: 19941774)
Vaccine X. 2019 Sep 17;3:100042. (PMID: 31660536)
Euro Surveill. 2022 Jun;27(26):. (PMID: 35775429)
Euro Surveill. 2016 Apr 21;21(16):. (PMID: 27124420)
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):365-370. (PMID: 35271561)
Euro Surveill. 2022 Sep;27(38):. (PMID: 36148674)
Influenza Other Respir Viruses. 2018 Jul;12(4):423-437. (PMID: 29125681)
Vaccine. 2013 Apr 19;31(17):2165-8. (PMID: 23499601)
Euro Surveill. 2019 Nov;24(48):. (PMID: 31796152)
Euro Surveill. 2013 Jan 31;18(5):. (PMID: 23399425)
Euro Surveill. 2022 Jun;27(26):. (PMID: 35775428)
Clin Infect Dis. 2022 Aug 24;75(1):e564-e571. (PMID: 35325923)
J Exp Med. 2013 Jul 29;210(8):1493-500. (PMID: 23857983)
Clin Infect Dis. 2016 Dec 29;64(5):544-550. (PMID: 28039340)
PLoS Med. 2011 Jan;8(1):e1000388. (PMID: 21379316)
-
Contributed Indexing:
-
Keywords: Europe; influenza; influenza vaccine; multicentre study; vaccine effectiveness
-
Substance Nomenclature:
-
0 (Influenza Vaccines)
-
Entry Date(s):
-
Date Created: 20230126 Date Completed: 20230131 Latest Revision: 20230213
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9835407
-
DOI:
-
10.1111/irv.13069
-
PMID:
-
36702797
-
Background: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE).
Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.
Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.
Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.
(© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
